VY-SOD 101
Alternative Names: VY SOD 101Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Voyager Therapeutics
- Class Gene therapies; Small interfering RNA
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 01 Dec 2022 Preclinical trials in Amyotrophic lateral sclerosis in USA (Intrathecal) prior to December 2022 (Voyager Therapeutics pipeline, December 2022)
- 09 Sep 2021 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (Intrathecal)
- 31 Dec 2019 Voyager Therapeutics announces intention to submit IND for VY SOD101 in Amyotrophic lateral sclerosis in 2019